Another bispecific, humanized IgG1 antibody which is beneath investigation is zenocutuzumab (MCLA-128), which functions by using two impartial mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells by using ADCC. MCLA-128 features by means of a ‘dock and block’ system whereby a person arm of the antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/